

## Specific Antigens to Distinguish *M. tuberculosis* from *M. avium*

Qun Liang<sup>1,2\*</sup>, Lingxia Zhang<sup>3\*</sup>, Zeng Tu<sup>1,4\*</sup>, Jingyu Wang<sup>1,2</sup>, Tao Hu<sup>1</sup>, Pengzhi Wang<sup>1</sup>, Weili Wu<sup>1</sup>, Qi Liu<sup>5</sup>, Yanlin Zhao<sup>6</sup>, Yan Li<sup>7#</sup>, Weijun Chen<sup>1,5#</sup>

<sup>1</sup>Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China

<sup>2</sup>Graduate University of the Chinese Academy of Sciences, Beijing, China

<sup>3</sup>Beijing 309th Hospital of PLA, Beijing, China

<sup>4</sup>Department of Pathogenic Biology, Chongqing Medical University, Chongqing, China

<sup>5</sup>Beijing Genomics Institute in Shenzhen, Shenzhen, China

<sup>6</sup>Beijing Tuberculosis and Thoracic Tumor research Institute, Beijing, China

<sup>7</sup>The Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, China

Email: liangqun82623@gmail.com, zhanglingxia7@yahoo.com.cn,

Tuz1980@126.com, icandowjy@yahoo.com.cn, hutao8426@126.com, wangpzh@genomics.org.cn,

wuwl@big.ac.cn, hellofqaa@126.com, zhaoyanlin@tb123.org, #liyanmd@yahoo.com.cn, #chenwj@genomics.org.cn

Received April 15, 2012; revised May 23, 2012; accepted June 4, 2012

### ABSTRACT

To distinguish *Mycobacterium tuberculosis* from *Mycobacterium avium*, specific *M. tuberculosis* antigens had been studied for improving the early differential diagnosis effect of tuberculosis caused by different *Mycobacterium*. The rabbit anti-*M. avium* sera and anti-*M. tuberculosis* sera were analyzed for antibody-based reactivity by matrix-assisted laser desorption-ionization mass spectrometry (MALDI-TOF Mass) against *M. tuberculosis* proteins. The immunoreactive spots, which were attributed to the proteins HspX, GroES and CFP-10, were mostly located at 10 - 60 kDa and PI 4 - 6, subsequently Western blotting result proved that HspX and CFP-10 were specific to *M. tuberculosis* and ELISA testing result of 30 *M. avium* positive sera showed that GroES were cross-reactive to *M. avium*. Lastly, positive and negative tuberculosis reference sera and based on the mechanism of indirect ELISA, the specificity and the sensitivity of the methods targeting the antibodies HspX, GroES or CFP-10 were evaluated at 37% and 26%, 12% and 97%, 81% and 98%, respectively. The combination of these three antibody detection methods allowed to reached a specificity of 42%, and of 39% without taken into account of the method targeting the GroES antibody. Using proteomics approach, we found three *M. tuberculosis* specific antigens showed good potential in tuberculosis diagnosis, providing basic study for serodiagnosis of tuberculosis.

**Keywords:** *Mycobacterium tuberculosis*; *Mycobacterium avium*; Mass Spectrometry; Immunodetection

### 1. Introduction

Tuberculosis (TB) remains a major cause of death in developing countries. It is also rising throughout the industrialized countries, partly as the cause of human immunodeficiency virus (HIV) infection. *Mycobacterium tuberculosis* complex (MTC) members such as *M. tuberculosis* are the pathogens of TB infection and *Nontuberculous mycobacteria* (NTM) such as *Mycobacterium avium* are responsible of mycobacteria [1,2]. Unfortunately, NTM is resistant to many general anti-TB drugs, leading the patients to suffer a years prolonged course and finally become chronic or refractory cases of mycobacteria [3,4]. However, clinically it is difficult to dis-

tinguish between them, because they are similar in clinical manifestations, imaging study, smear and culture, tuberculin tests and pathological examination [5-7]. Therefore, the rapid identification of *M. tuberculosis* and *M. avium* is of extreme importance to diagnosis, effective chemotherapy and control transmission of TB.

Represented by two-dimensional gel electrophoresis (2-D) and mass spectrometry (MS) technology, proteomics has provided some encouraging results in TB research [8-10]. So far, important antigens of *M. tuberculosis* have been identified such as the 38-kDa antigen, early secreted antigenic target (ESAT-6), antigen 85B, the proteins encoded by Rv3872 [11,12]. However, the cross-reaction between *M. tuberculosis* and *M. avium* makes these antigens unable to distinguish these myco-

\*These authors contributed equally to this article.

#Corresponding authors.

bacterial species and consequently differentiate those respective infections [13]. Only a few secreted proteins such as 14-kDa protein and CFP-10 have been further characterized which was demonstrated by Western blotting in culture filtrates of *M. avium* but was not detected in *M. tuberculosis* [14]. CFP-10, molecular weight of 10 kDa, mainly existed in *M. tuberculosis* culture filtrate. Previous data have shown that it is a specific potential antigen to *M. tuberculosis* [15,16]. Renshaw *et al.* [17] reported that BCG and NTM were lack of CFP-10 coding. HspX-14 was predicted to be an important membrane antigen, which increased expression along with *M. tuberculosis* growing into stable phase from logarithmic phase [18] and in anaerobic condition [19]. Some data also showed HspX-14 could induce humoral immune response [20,21]. GroES, a molecular chaperone protein, joints participation in protein folding, assembly, transport and degradation [22]. The high abundance of GroES possibly led antigen presenting cells to secrete many small peptides which could induce the host produced a strong immunological response [23]. These reports suggested that these proteins may be the *M. tuberculosis*-specific antigenicity.

Comparison of immunoblot profiles of rabbit anti-*M. tuberculosis* sera and rabbit anti-*M. avium* sera reacting with extracts of *M. tuberculosis* could detect specific antigens allowing to distinguish easily these two mycobacteria species and helped the serodiagnostic test for tuberculosis.

## 2. Materials

*Mycobacterium tuberculosis* H37Rv, rabbit anti-*M. tuberculosis* sera and rabbit anti-*M. avium* sera were obtained from Tuberculosis Research Institute of the People's Liberation Army Hospital 309 (Beijing, China).

300 sera from healthy blood donors were collected from Beijing Red-cross blood Central which were tested negatively to TB by Elisa kits (Chengdu Yongan Pharmaceutical Co. Ltd).

100 sera from *M. tuberculosis* patients were collected in 309 Hospital (Beijing, China). Basis of diagnosis: Two sputum samples examined by smear microscopy-stained for acid-fast bacilli or AFB are positive and chest X-ray visualizes the chest shadow caused by tubercular lesion. Then used COBAS AMPLICOR™ *M. tuberculosis* Kit (Roche) to confirm.

30 sera from *M. avium* patients were collected in 309 Hospital (Beijing, China). Basis of diagnosis: Used COBAS AMPLICOR™ *M. avium* Kit (Roche) to detect *M. avium* and used COBAS AMPLICOR™ *M. tuberculosis* Kit (Roche) to confirm they were not infected by *M. tuberculosis*.

200 sera from purified protein derivative (PPD)-posi-

tive healthy body-examining people were collected in Affiliated Hospital of the Academy of Military Medical Sciences.

## 3. Methods

### 3.1. Protein Preparation

*M. tuberculosis* H37Rv was cultured in modified Sauton medium for 4 weeks and heat-inactivated at 80°C for 1 hr. The bacteria were harvested by centrifugation and were washed three times with 10 mM Tris buffer (pH 7.4), then suspended in 500 µl lysate (0.3% SDS, 200 mM DTT, 50 mM Tris, pH 7) and sonicated for 30 min (250 W, 2 sec pulse-on, 4 sec pulse-off intervals), subsequently added the Benzonase nuclease (1:20; Novagen, Merck KgaA, Darmstadt, Germany) and kept at 4°C for 1 hr, and then centrifuged at 22,300 g for 30 min. Used 2-D Clean-up Kit (GE Healthcare, Fairfield, USA) to purified protein.

### 3.2. 2-D PAGE

Samples of 200 µg protein suspended in rehydration buffer (6 M Carbamide, 0.71 M SDS, 0.375 M Tris pH 8.8, 20% glycerol) were applied on immobilized pH 4 - 7 linear gradient strips (13 cm; GE Healthcare). Focusing at 20°C using the following four-step program: a) 50 V, 6 hr; b) 500 V, 1 hr; c) 1000 V, 1 hr; d) 8000 V constant until 66,000 Vh. The current limit was set at 50 µA/strip. After isoelectric focusing (IEF), each strip was equilibrated for 15 min in equilibration buffer I (rehydration buffer, 0.13 M DTT) followed by equilibration buffer II (rehydration buffer, 0.14 M iodoacetamide) for 15 min. The second dimension separation was performed in uniform 12.5% SDS-PAGE gels. Then silver stained the gels.

### 3.3. Western Blotting

Preparing for Western blotting, proteins was electrophoretically transferred by using TE70 Semi-Dry Transfer (Amersham Pharmacia Biotech, Uppsala, Sweden) to 0.2-µm-pore-size polyvinylidene difluoride membrane (Immun-Blot PDVF membrane; Bio-Rad, Hercules, CA), which was then washed and blocked in Tris-buffered saline-Tween 20 (TBS-T) containing 1% Tween 20 and 5% non-fat dry milk for 120 min, next incubated in the rabbit anti-*M. tuberculosis* and anti-*M. avium* sera (both 1:250 TBS-T diluted) for 2 hr, then reacted with horseradish peroxidase labeled goat anti-rabbit IgG antibody (Santa Cruz Biotechnology, Santa Cruz, USA) (1:2500 TBS-T diluted) for 1 hr, subsequently washed extensively in TBS-T and then add freshly prepared DAB solution (Beijing Saichi Shengwu Keji, Beijing, China) for color. Signal was detected by using UMAX scanner and

analyzed with ImageMaster 2D software for variance.

### 3.4. MALDI-TOF MASS

The excised protein spots were destained in 50 mM ammonium bicarbonate/acetonitrile (1:1) until colorless, dehydrated with acetonitrile, reduced in 25 mM ammonium bicarbonate/acetonitrile (1:1). The gel pieces were dried white by acetonitrile and speedvac. Then incubated at 37°C overnight with 25 mM ammonium bicarbonate diluted trypsin. The reaction was stopped by adding 1% trifluoroacetic acid (final concentrations 0.1%), Peptide mixtures were applied to AnchorChip (Bruker Daltonics Inc. Billerica, USA) and analyzed by MALDI-TOF (Bruker Daltonik) using  $\alpha$ -4-hydroxycinnamic acid as matrix with positive ion detection mode.

For peptide mass fingerprinting (PMF) analysis, MASCOT service provided by the Matrixscience Company ([www.matrixscience.com](http://www.matrixscience.com)) was used.

### 3.5. Cloning, Expression, Purification and Immunization Verification of the Recombinant Protein

Obtained from *M. tuberculosis* H37Rv genomic DNA, HspX antigen gene was prepared by amplification using appropriate primers (forward: 5'-CGCAATTCATATG-GCCACCACCCTTCCCGTTC-3' and reverse: 5'-GCC-CTAAGCTTTCAGTTGGTGGACCGGATCTG-3') carried Nde I and Hind III sites (underlined sequences). GroES antigen gene used forward: 5'-GGGAATC-CATATGGTGGCGAAGGTGAACATC-3' and reverse: 5'-CGGAAGCTTCTACTTGGAAACGACGGC-3' carried the same sites (underlined sequences). While CFP-10 antigen gene used forward: 5'-CGTAGCTAGC-GGTGGCGGCATGGCAGAGATGAAGACCGA-3' and reverse: 5'-CCGGAATTCATCATTAAGTGTCCA-CCGAAGCCCATTGCGAGGACA-3' carried Nhe I and EcoR I sites.

The gel-purified PCR products were digested by appropriate restriction enzyme, and ligated to pET-28a(+) vector (HspX and GroES PCR products) or pET-30a(+) vector (CFP-10 PCR product) (Novagen).

*Escherichia coli* BL21 (DE3) harboring recombinant plasmids were grown in LB medium containing 50 mol/l of Kanamycin overnight at 37°C, then induced with isopropyl thiogalactoside (1 mmol/l) at 37°C for 4 hr. The harvested cells were resuspended in phosphate-buffered saline (PBS) containing DNAase, and then lysed by sonication (the same model setted above, 20 min). The proteins with His-6 label were further purified by anion exchange chromatography.

Western blots of three proteins were all probed with rabbit anti-*M. tuberculosis* sera (1:1000) and rabbit anti-*M. avium* sera (1:1000) at 37°C for 2 hr, followed

reacted with Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:3500, BGI-GBI Biotech, Beijing, China) at 37°C for 1 hr. The band density was calculated by image software.


### 3.6. Immunological Assessment

The reactivity of each protein was tested with 100 patients infected by *M. tuberculosis*, 30 patients infected by *M. avium* and 200 PPD-positive healthy subjects. First, 100  $\mu$ l of each protein (The optimum concentration after contrast were HspX-14: 0.2  $\mu$ g/ml, GroES: 5  $\mu$ g/ml, CFP-10: 2.5  $\mu$ g/ml) diluted in blocking buffer (0.05% Tween-20, 1% BSA, 0.01 M PBS, pH 7.4) was added to wells of streptavidin coated ELISA plates and incubated at 37°C for 1 hr. Subsequently, 100  $\mu$ l of diluted sera (1:50 in PBST, containing 0.1% BSA) from healthy subjects and patients was added and incubated at 37°C for 1 hr (triplicates). After five times washes with PBST, 100  $\mu$ l of mixture of HRP-conjugated goat anti-Human IgG (1:40,000, BGI) was added to each well and incubated at 37°C for 1 hr. After six times washes with PBST, the optical density (OD) value was measured at 450 nm/630 nm. Concerning the sera collected by the Beijing Red-cross Blood Central from 300 blood donors, the cutoff value determining the positive responses was the mean optical density plus two standard deviations.

## 4. Results

### 4.1. MS Identification of *M. tuberculosis* Antigens

The proteins separated by 2-D PAGE gel (Figure 1) were transferred to PVDF membrane and reacted with



**Figure 1.** 2-D PAGE gel of *Mycobacterium tuberculosis* H37Rv proteins.

anti-*M. tuberculosis* and anti-*M. avium* sera respectively. Most immunoreactive spots located at PI 4 - 6 and 10 - 60 kDa in molecular mass. Ten spots were recognized exclusively by anti-*M. tuberculosis* sera and identified as GroES, HspX and CFP-10 by PMF using MALDI-TOF MASS (Table 1), the protein corresponding to spots 6-10 were not detected in 2-D PAGE gel, while spots in areas (E-I) were reacted with both anti-*M. tuberculosis* and anti-*M. avium* sera (Figure 2, Table 1). Spots in areas A - D only reacted with anti-*M. avium* sera.

#### 4.2. Expression, Purification and Immunogenicity of HspX, GroES and CFP-10

The purified HspX protein, appeared as a 17 kDa band

on SDS-polyacrylamide gel (Figure 3). GroES and CFP-10 were approximately 14 kDa, which were similar to the theoretical molecular weight.

Using Western blotting analysis, rabbit anti-*M. tuberculosis* sera showed strong reactivity with HspX, GroES and CFP-10, whereas rabbit anti-*M. avium* sera did not react with HspX and CFP-10, and showed tenuous reactivity with GroES (Figure 4), checking that HspX, CFP-10 and GroES were specific to *M. tuberculosis* compared to avium species.


#### 4.3. Immunological Assessment

The cutoff values for IgG were 0.14 to HspX, 0.12 to GroES and 0.1 to CFP-10. HspX, GroES and CFP-10 proteins were detected in 37% (37 of 100), 26% (26 of

**Table 1.** List of antigens that reacted only with anti-*M. tuberculosis* sera (spots 1 - 5) and antigens that reacted both with anti-*M. tuberculosis* and anti-*M. avium* sera (areas E - H).


Location	Protein Name	NCBI nr Accession no.	Mr	pI	Sequence Coverage	Score <sup>a</sup>
Spot 1	GroES	gi 16796865	10499	4.51	59%	68
Spot 2	CFP-10	gi 15611010	10787	4.59	64%	71
Spot 3/4/5	HspX-14	gi 15609168	162176679	5.00	29%	100
Area E	protein dnaK	gi 15607491	0	4.85	39%	166
Area F	60 KDa chaperonin	gi 1449370	56692	4.85	46%	211
Area G	L Elongation factor Tu	gi 15607825	43566	5.28	87%	267
Area H	35 KDa protein	gi 57117019	29240	5.71	52%	151

<sup>a</sup>The scores greater than 63 are significant ( $P < 0.05$ ).




**Figure 2.** Screening of antigens in *M. tuberculosis* with anti-*M. avium* sera (A) and anti-*M. tuberculosis* sera (B) by 2-D PAGE. Areas E-I reacted with both sera. Spots 1 - 10 showed reactivity with anti-*M. tuberculosis* sera exclusively, while areas A-D only reacted with anti-*M. avium* sera.





**Figure 3. Expression of HspX, GroES and CFP-10 antigens (12.5% SDS-PAGE).**



**Figure 4. Validation of the antigens specific to *M. tuberculosis*. Western blotting analysis of the equal amount expressed HspX, GroES and CFP-10 proteins separated by SDS-PAGE, were performed with either anti-*M. tuberculosis* or anti-*M. avium* sera for 3 times.**

100) and 12% (12 of 100) of *M. tuberculosis* patients sera respectively (**Table 2**). Moreover, two sera of the samples were tested positive with CFP-10 but negative with the other two proteins and another three sera were positive with GroES protein solely. While only GroES

**Table 2. Serological reactivity of CFP-10, GroES and HspX-14 in *M. tuberculosis* patients, *M. avium* patients and healthy PPD+ individuals.**

Status	No. of persons	No. of samples positive by ELISA for:						
		C <sup>a</sup>	G <sup>b</sup>	H <sup>c</sup>	C+G	C+H	G+H	C+G+H
<i>M. tuberculosis</i> +	100	12	26	37	28	39	40	42
<i>M. avium</i> +	30	0	7	0	7	0	7	7
Healthy, PPD+	200	3	35	5	36	6	37	38

<sup>a</sup>C: CFP-10; <sup>b</sup>G: GroES; <sup>c</sup>H: HspX-14.

protein (7 of 30) was detected in sera of *M. avium* patients.

To evaluate the specificity, two hundred of sera from PPD-positive health body-examining people were tested. The specificity of HspX, GroES and CFP-10 were 97.5% (195 of 200), 82.5% (165 of 200) and 98.5% (197 of 200), respectively (**Table 2**). Similarly, 1 sera was tested positive only with CFP-10, while 2 sera only with HspX-14.

## 5. Discussion

At present, TB remains a serious threat to human health. A rapid diagnostic method of early stage of TB infection will undoubtedly play a decisive role in TB control [24], yet various similar pathological manifestations make them difficult to distinguish [5-7]. Recently, more and more *M. avium* infection has been reported [25-28]. However, the research about the distinction between *M. tuberculosis* and *M. avium* is rare [14].

Using a serological proteomic approach to detect specifically by identifying candidate antigen has been reported by previous research [8-10]. Due to high lipid content of *M. tuberculosis*, we chose 2-D Clean-up kit to purify the crude protein and optimized some other proteomics experimental condition of *M. tuberculosis*, including the IEF voltage settings, staining method, transfer membrane current and time settings. Three proteins (CFP-10, GroES, HspX-14) were identified as potentially specific antigen of anti-*M. tuberculosis* by 2-D PAGE, Western blotting and MALDI-TOF methods in our study. CFP10, one of the antigens selected by our method was consistent with what was reported [14], which suggested the approach could screen out specific antigens.

The result of Immunoblotting assays showed that CFP-10 and HspX-14 only reacted with the anti-*M. tuberculosis* sera while the GroES protein cross-reacted with the anti-*M. avium* sera slightly (**Figure 4**).

The result of testing for specificity of these recombinant proteins showed that the specific response to protein GroES was relatively lower. *M. tuberculosis* GroES,

having a part homology sequence with human homologous protein, often causes the emergence of spontaneous autoimmune diseases such as rheumatoid arthritis, systemic sclerosis, psoriasis, and ankylosing spondylitis [28, 29]. It may be the causes of lower specificity.

The result of evaluating the sensitivity of these recombinant proteins showed a low sensitivity (37%, 26%, 12%). This was consistent with the previous *M. tuberculosis* antibody detection studies [16,30,31]. Nonetheless, CFP-10, GroES and HspX-14 proteins as test antigens were complementary in detecting *M. tuberculosis* specific antibodies and could effectively improve the detection of *M. tuberculosis* antibodies (42%). Ignoring the contribution of GroES, the detection ratio of CFP-10 and HspX-14 proteins as a test antigen could reach 39%.

In summary, we detected three *M. tuberculosis* specific antigens, which could be used in order to distinguish *M. tuberculosis* from *M. avium*. By system research of HspX-14, GroES and CFP-10, we found that HspX-14 and CFP-10 showed better potentiality in TB diagnosis.

## 6. Acknowledgements

The work was supported by the research funding from Infectious Diseases Special Project, Minister of Health of China (2008ZX10003—009) and Beijing Science and Technology Program (Z08050703080801).

## 7. Disclosure

I certify that all my affiliations with or financial involvement in, within the past 5 years and foreseeable future, any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript are completely disclosed.

## REFERENCES

- [1] D. S. Prince, D. D. Peterson and R. M. Steiner, "Infection with *Mycobacterium avium* Complex in Patients without Predisposing Conditions," *New England Journal of Medicine*, Vol. 321, No. 13, 1989, pp. 863-868. [doi:10.1056/NEJM198909283211304](https://doi.org/10.1056/NEJM198909283211304)
- [2] A. I. Zumla and J. Grange, "Nontuberculous mycobacterial Pulmonary Infections," *Clinics in Chest Medicine*, Vol. 23, No. 2, 2002, pp. 369-376. [doi:10.1016/S0272-5231\(01\)00011-9](https://doi.org/10.1016/S0272-5231(01)00011-9)
- [3] M. Payton, R. Auty, R. Delgoda, M. Everett and E. Sim, "Cloning and Characterization of Arylamine n-Acetyltransferase Genes from *Mycobacterium smegmatis* and *Mycobacterium tuberculosis*: Increased Expression Results in Isoniazid Resistance," *Journal of Bacteriology*, Vol. 184, No. 4, 1999, pp. 1343-1347.
- [4] D. E. Griffith, B. A. Brown, P. Cegielski, D. T. Murphy and R. J. Wallace Jr., "Early Results (at 6 Months) with Intermittent Clarithromycin Including Regimens for Lung Disease Due to *Mycobacterium avium* Complex," *Clinical Infectious Diseases*, Vol. 30, No. 2, 2000, pp. 288-292. [doi:10.1086/313644](https://doi.org/10.1086/313644)
- [5] R. J. Seballos, A. L. Walsh and A. C. Mehta, "Clinical Evaluation of a Liquid Chemical Sterilization System for the Flexible Bronchoscope," *Journal of Bronchology*, Vol. 2, No. 3, 1995, pp. 192-199. [doi:10.1097/00128594-199507000-00005](https://doi.org/10.1097/00128594-199507000-00005)
- [6] C. F. Von Reyn, D. E. Williams, C. R. Horsburgh, A. S. Jaeger, B. J. Marsh, K. Haslovk and M. Magnusson, "Dual Skin Testing with *Mycobacterium avium* Sensitin and Purified Protein Derivative to Discriminate Pulmonary Disease Due to *M. avium* Complex from Pulmonary Disease Due to *Mycobacterium tuberculosis*," *Journal of Infectious Diseases*, Vol. 177, No. 3, 1998, pp. 730-736. [doi:10.1086/514225](https://doi.org/10.1086/514225)
- [7] A. M. Middleton, M. V. Chadwick, A. G. Nicholson, R. Wilson, D. J. Thomson, S. Kirkham and J. K. Sheehan, "Interaction between Mycobacteria and Mucus on a Human Respiratory Tissue Organ Culture Model with an Air Interface," *Experimental Lung Research*, Vol. 30, No. 1, 2004, pp. 17-29. [doi:10.1080/01902140490252876](https://doi.org/10.1080/01902140490252876)
- [8] P. R. Jungblut, E. C. Muller, J. Mattow and S. H. E. Kaufmann, "Proteomics Reveals Open Reading Frames in *Mycobacterium tuberculosis* H37Rv Not Predicted by Genomics," *Infection and Immunity*, Vol. 69, No. 9, 2001, pp. 5905-5907. [doi:10.1128/IAI.69.9.5905-5907.2001](https://doi.org/10.1128/IAI.69.9.5905-5907.2001)
- [9] J. Starck, G. Källenius, B. I. Marklund, D. I. Andersson and T. Åkerlund, "Comparative Proteome Analysis of *Mycobacterium tuberculosis* Grown under Aerobic and Anaerobic Conditions," *Microbiology*, Vol. 150, No. 11, 2004, pp. 3821-3829. [doi:10.1099/mic.0.27284-0](https://doi.org/10.1099/mic.0.27284-0)
- [10] S. W. Ryoo, Y. K. Park, S. N. Park, Y. S. Shim, H. Liew, S. Kang and G. H. Bai, "Comparative Proteomic Analysis of Virulent Korean *Mycobacterium tuberculosis* K-Strain with Other Mycobacteria Strain Following Infection of U-937 Macrophage," *Journal of Microbiology*, Vol. 45, No. 3, 2007, pp. 268-271.
- [11] P. Andersen, A. B. Andersen, A. L. Sorensen and S. Nagai, "Recall of Longlived Immunity to *Mycobacterium tuberculosis* Infection in Mice," *Journal of Immunology*, Vol. 154, No. 7, 1995, pp. 3359-3372.
- [12] E. D. Chan, R. Reves, J. T. Belisle, P. J. Brennan and W. E. Hahn, "Diagnosis of Tuberculosis by a Visually Detectable Immunoassay for Lipoarabinomannan," *American Journal of Respiratory and Critical Care Medicine*, Vol. 161, No. 5, 2000, pp. 1713-1719.
- [13] U. Demkow, M. Filewska, B. Bialas, M. Szturmowicz, T. Zielonka, S. Wesolowski, J. Kuś, J. Ziolkowski, E. Augustynowicz-Kopec, Z. Zwolska, E. Skopińska-Rábewska and E. Rowińska-Zakrzewska, "Antimycobacterial Antibody Level in Pleural, Pericardial and Cerebrospinal Fluid of Patients with Tuberculosis," *Pneumologia I Alergologia Polska*, Vol. 72, No. 3, 2004, pp. 105-110.
- [14] I. Olsen, L. J. Reitan and H. G. Wiker, "Distinct Differences in Repertoires of Low-Molecular-Mass Secreted Antigens of *Mycobacterium avium* Complex and *Mycobacterium tuberculosis*," *Journal of Clinical Microbiol-*

- ogy, Vol. 38, No. 12, 2000, pp. 4453-4458.
- [15] D. C. Dillon, M. R. Alderson, C. H. Day, T. Bement, A. Campos-Neto, Y. A. W. Skeiky, T. Vedvick, R. Badaro, S. G. Reed and R. Houghton, "Molecular and Immunological Characterization of *Mycobacterium tuberculosis* CFP-10, an Immunodiagnostic Antigen Missing in *Mycobacterium bovis* BCG," *Journal of Clinical Microbiology*, Vol. 38, No. 9, 2000, pp. 3285-3290.
- [16] L. A. H. van Pinxteren, P. Ravn, E. M. Agger, J. Pollock and P. Andersen, "Diagnosis of Tuberculosis Based on the Two Specific Antigens ESAT-6 and CFP10," *Clinical and Vaccine Immunology*, Vol. 7, No. 2, 2000, pp. 155-160. [doi:10.1128/CDLI.7.2.155-160.2000](https://doi.org/10.1128/CDLI.7.2.155-160.2000)
- [17] P. S. Renshaw, K. L. Lightbody, V. Veverka, F. W. Muskett, G. Kelly, T. A. Frenkiel, S. V. Gordon, R. G. Hewinson, B. Burke, J. Norman, R. A. Williamson and M. D. Carr, "Structure and Function of the Complex Formed by the Tuberculosis Virulence Factors CFP-10 and ESAT-6," *The EMBO Journal*, Vol. 24, No. 23, 2005, pp. 2491-2498. [doi:10.1038/sj.emboj.7600732](https://doi.org/10.1038/sj.emboj.7600732)
- [18] Y. Hu, F. Movahedzadeh, N. G. Stoker and A. R. M. Coates, "Deletion of the *Mycobacterium tuberculosis* Alpha-Crystallin-Like HspX Gene Causes Increased Bacterial Growth *in Vivo*," *Infection and Immunity*, Vol. 74, No. 2, 2006, pp. 861-868. [doi:10.1128/IAI.74.2.861-868.2006](https://doi.org/10.1128/IAI.74.2.861-868.2006)
- [19] R. Colangeli, J. S. Spencer, P. Bifani, A. Williams, K. Lyashchenko, M. A. Keen, P. J. Hill, J. Belisle and M. L. Gennaro, "MTSA-10, the Product of the Rv3874 Gene of *Mycobacterium tuberculosis*, Elicits Tuberculosis-Specific, Delayed-Type Hypersensitivity in Guinea Pigs," *Infection and Immunity*, Vol. 68, No. 2, 2000, pp. 990-993. [doi:10.1128/IAI.68.2.990-993.2000](https://doi.org/10.1128/IAI.68.2.990-993.2000)
- [20] G. H. Bothamley, "Epitope-Specific Antibody Levels Demonstrate Recognition of New Epitopes and Changes in titer but Not Affinity during Treatment of Tuberculosis," *Clinical and Vaccine Immunology*, Vol. 11, No. 5, 2004, pp. 942-951. [doi:10.1128/CDLI.11.5.942-951.2004](https://doi.org/10.1128/CDLI.11.5.942-951.2004)
- [21] A. Geluk, M. Y. Lin, K. E. Meijgaarden, E. M. S. Leyten, K. L. M. C. Franken, T. H. M. Ottenhoff and M. R. Klein, "T-Cell Recognition of the HspX Protein of *Mycobacterium tuberculosis* Correlates with Latent *M. tuberculosis* Infection but Not with *M. bovis* BCG Vaccination," *Infection and Immunity*, Vol. 75, No. 6, 2007, pp. 2914-2921. [doi:10.1128/IAI.01990-06](https://doi.org/10.1128/IAI.01990-06)
- [22] J. C. Ranford, A. R. Coates and B. Henderson, "Chaperonins Are Cell-Signalling Proteins: The Unfolding Biology of Molecular Chaperones," *Molecular Medicine*, Vol. 2, No. 8, 2000, pp. 1-17.
- [23] I. Rosenkrands, K. Weldingh, P. Ravn, L. Brandt, P. Hojrup, P. B. Rasmussen, A. R. Coates, M. Singh, P. Mascagni and P. Andersen, "Differential T-Cell Recognition of Native and Recombinant *Mycobacterium tuberculosis* GroES," *Infection and Immunity*, Vol. 67, No. 11, 1999, pp. 5552-5558.
- [24] P. Nunn, "The Global Epidemic. The Present Epidemiology of Tuberculosis," *Scottish Medical Journal*, Vol. 45, No. 5, 2000, pp. 6-7.
- [25] R. J. Wilkinson, K. Haslov, R. Rappuoli, F. Giovannoni, P. R. Narayanan, C. R. Desai, H. M. Vordermeier, J. Paulsen, G. Pasvol, J. Lvanyi and M. Singh, "Evaluation of the Recombinant 38-Kilodalton Antigen of *Mycobacterium tuberculosis* as a Potential Immunodiagnostic Reagent," *Journal of Clin Microbiology*, Vol. 35, No. 3, 1997, pp. 553-557.
- [26] K. Lyashchenko, R. Colangeli, M. Houde, H. A. Jahdali, D. Menzies and M. L. Gennaro, "Heterogeneous Antibody Responses in Tuberculosis," *Infection and Immunity*, Vol. 66, No. 8, 1998, pp. 3936-3940.
- [27] K. R. U. Devi, B. Ramalingam and A. Raja, "Antibody Response to *Mycobacterium tuberculosis* 30 and 16 kDa Antigens in Pulmonary Tuberculosis with Human Immunodeficiency Virus Coinfection," *Diagnostic Microbiology & Infectious Disease*, Vol. 6, No. 3, 2002, pp. 205-209.
- [28] G. V. Kanaujia, M. A. Garcia, D. M. Bouley, R. Peters and M. L. Gennaro, "Detection of Early Secretory Antigenic Target-6 Antibody for Diagnosis of Tuberculosis in Non-Human Primates," *Comparative Medicine*, Vol. 53, No. 6, 2003, pp. 602-606.
- [29] U. Zugel and S. H. E. Kaufmann, "Role of Heat Shock Proteins in Protection from and Pathogenesis of Infectious Diseases," *Clinical Microbiology Reviews*, Vol. 12, No. 1, 1999, pp. 19-39.
- [30] M. J. Elhay, T. Oettinger and P. Andersen, "Delayed-Type Hypersensitivity Responses to ESAT-6 and MPT64 from *Mycobacterium tuberculosis* in the Guinea Pig," *Infection and Immunity*, Vol. 66, No.7, 1998, pp. 3454-3456.
- [31] H. Målen, F. S. Berven, K. E. Fladmark and H. G. Wiker, "Comprehensive Analysis of Exported Proteins from *Mycobacterium tuberculosis* H37Rv," *Proteomics*, Vol. 7, No. 10, 2007, pp. 1702-1718. [doi:10.1002/pmic.200600853](https://doi.org/10.1002/pmic.200600853)